Association Between Qmax/eGFR Ratio and LUTS Severity in Men Over 40
NCT ID: NCT07055425
Last Updated: 2025-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2025-09-01
2026-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Benign Prostatic Hyperplasia and Glycosaminoglycan
NCT03955484
Uroflowmetry Curve Types and IPSS in Men With LUTS
NCT07016776
Real World Data on Management of Male LUTS
NCT03075449
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
NCT00710749
Ultrasound IPP to Predict Response to Medical Therapy in LUTS/BPH
NCT07306767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will undergo standard non-invasive assessments including uroflowmetry, serum creatinine testing (for eGFR calculation), and will complete the International Prostate Symptom Score (IPSS) questionnaire. The IPSS includes both total symptom score and quality of life (QoL) component. The primary objective is to evaluate the correlation between the Qmax/eGFR ratio and IPSS total score. Secondary objectives include the relationship between Qmax/eGFR and QoL scores, as well as analysis based on prostate volume categories.
This study seeks to identify whether the Qmax/eGFR ratio may serve as a composite marker reflecting both voiding efficiency and renal function in the clinical assessment of LUTS, potentially supporting more individualized decision-making in urological practice.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Men Over 40 With LUTS
Male patients aged 40 years or older presenting with lower urinary tract symptoms (LUTS), who undergo uroflowmetry and renal function testing, and complete the IPSS questionnaire. No interventions will be applied. This group will be prospectively observed for the association between Qmax/eGFR ratio and symptom severity.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide informed consent
* Willing and able to undergo uroflowmetry and blood testing
* Able to complete the IPSS questionnaire, including the QoL item
* Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m²
Exclusion Criteria
* Diagnosed or suspected prostate cancer
* Active urinary tract infection (based on clinical symptoms or urinalysis)
* Neurological conditions affecting bladder function (e.g., Parkinson's disease, spinal cord injury)
* Presence of an indwelling urinary catheter at enrollment
* eGFR \< 30 mL/min/1.73m²
* Inability to perform uroflowmetry or complete clinical evaluations
40 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marmara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tarik Emre Sener
Assoc. Prof.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAR.UAD.0024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.